Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

David Lynch to Cystic Fibrosis Transmembrane Conductance Regulator

This is a "connection" page, showing publications David Lynch has written about Cystic Fibrosis Transmembrane Conductance Regulator.

 
Connection Strength
 
 
 
0.399
 
  1. Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Lynch DA, Taylor-Cousar JL. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes. Ann Am Thorac Soc. 2022 01; 19(1):12-19.
    View in: PubMed
    Score: 0.164
  2. Beswick DM, Humphries SM, Balkissoon CD, Vladar EK, Ramakrishnan VR, Lynch DA, Taylor-Cousar JL. Machine learning evaluates improvement in sinus computed tomography opacification with CFTR modulator therapy. Int Forum Allergy Rhinol. 2021 05; 11(5):953-954.
    View in: PubMed
    Score: 0.152
  3. Beswick DM, Humphries SM, Miller JE, Balkissoon CD, Khatiwada A, Vladar EK, Ramakrishnan VR, Lynch DA, Taylor-Cousar JL. Objective and patient-based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy. Int Forum Allergy Rhinol. 2022 11; 12(11):1435-1438.
    View in: PubMed
    Score: 0.042
  4. Beswick DM, Humphries SM, Balkissoon CD, Strand M, E Miller J, Khatiwada A, Vladar EK, Lynch DA, Taylor-Cousar JL. Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del. Int Forum Allergy Rhinol. 2022 07; 12(7):963-966.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)